How Have the Numbers Shaped Up for Ascendis Pharma A/S Stock Forecast, Price & News (NASDAQ:ASND)

0
109

Earnings results for Ascendis Pharma A/S Stock Forecast, Price & News (NASDAQ:ASND)

Ascendis Pharma A/S is expected* to report earnings on 08/27/2020 after market close. The report will be for the fiscal Quarter ending Jun 2020. According to Zacks Investment Research, based on 5 analysts’ forecasts, the consensus EPS forecast for the quarter is $-1.6600000000000001. The reported EPS for the same quarter last year was $-1.4.

Ascendis Pharma A/S last announced its earnings data on May 19th, 2020. The biotechnology company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.43) by $0.11. The business earned $2.45 million during the quarter, compared to analyst estimates of $2.66 million. Ascendis Pharma A/S has generated ($5.25) earnings per share over the last year. Ascendis Pharma A/S has confirmed that its next quarterly earnings report will be published on Thursday, August 27th, 2020.

Analyst Opinion on Ascendis Pharma A/S Stock Forecast, Price & News (NASDAQ:ASND)

11 Wall Street analysts have issued ratings and price targets for Ascendis Pharma A/S in the last 12 months. Their average twelve-month price target is $171.91, predicting that the stock has a possible upside of 23.26%. The high price target for ASND is $208.00 and the low price target for ASND is $145.00. There are currently 11 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Ascendis Pharma A/S has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $171.91, Ascendis Pharma A/S has a forecasted upside of 23.3% from its current price of $139.47. Ascendis Pharma A/S has only been the subject of 2 research reports in the past 90 days.

Dividend Strength: Ascendis Pharma A/S Stock Forecast, Price & News (NASDAQ:ASND)

Ascendis Pharma A/S does not currently pay a dividend. Ascendis Pharma A/S does not have a long track record of dividend growth.

Insiders buying/selling: Ascendis Pharma A/S Stock Forecast, Price & News (NASDAQ:ASND)

In the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock. 40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.

Earnings and Valuation of Ascendis Pharma A/S Stock Forecast, Price & News (NASDAQ:ASND

Earnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($6.47) to ($5.41) per share. The P/E ratio of Ascendis Pharma A/S is -26.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Ascendis Pharma A/S is -26.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Ascendis Pharma A/S has a P/B Ratio of 8.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here